Stay updated with breaking news from Beta Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RNA interference clinical trial pipeline constitutes 85+ key companies continuously working towards developing 100+ RNA interference therapies, analyzes DelveInsight LAS VEGAS, Nov. 1,
/PRNewswire/ -- DelveInsight's 'RNA Interference Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed, and...
/PRNewswire/ -- The "Global CD47 Inhibitor Drug Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global CD47...
Source: Xinhua| Editor: huaxia Video PlayerClose HANGZHOU, Dec. 17 (Xinhua) -- Ensartinib hydrochloride, a targeted drug for lung cancer developed by a Chinese firm, has been available in hospitals and pharmacies nationwide since Wednesday, according to its developer Beta Pharma. The Guangzhou-based Sun Yat-sen University Cancer Center prescribed the medication on Wednesday, first in China. Lung cancer is China's leading cause of mortality and morbidity in malignant tumor diseases, among which about 80 to 85 percent are non-small cell lung cancers (NSCLCs). Anaplastic Lymphoma Kinase (ALK), o...